Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen is a significant win for IPG Mediabrands after Amazon moved its massive media business from Initiative to WPP and ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Foundations Investment Advisors LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 11.5% in the 3rd ...

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $380.00.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Amgen (AMGN – Research Report), with a ...